You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 2
  • 629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor

Citation Tools

Article menu

Download PDFPDF

Regular Abstracts – Part 2
Clinical Trial Completed
629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Kim TM, Ngamphaiboon N, Lee KH, et al
629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0629-C